| ²é¿´: 3523 | »Ø¸´: 2 | ||||
Ò©Ãû¿µµÂгæ (³õÈëÎÄ̳)
|
[½»Á÷]
Ò©Ã÷¿µµÂÊÕ¹º°ÙÆæÉúÎï ÒÑÓÐ1È˲ÎÓë
|
|
10ÔÂ14ÈÕ£¬Ò©Ã÷¿µµÂÐû²¼ÊÕ¹º°ÙÆæÉúÎABGENT£©¹«Ë¾¡£°ÙÆæÉúÎïÊÇÒ»¼Ò¿ª·¢¡¢Éú²ú¼°ÏúÊÛ¿¹ÌåºÍÕï¶ÏÊÔ¼ÁµÄÉúÎï¼¼Êõ¹«Ë¾£¬ÔÚËÕÖÝ£¬ÉϺ££¬¼°ÃÀ¹úÊ¥µØÑǸç¾ùÓÐÔËӪʵÌ壬¹²ÓÐÔ±¹¤150¶àÃû¡£ °ÙÆæÉúÎï×Ô2001ÄêÔÚÃÀ¹úÊ¥µØÑǸç³ÉÁ¢ÒÔÀ´£¬ÔÚÆä´´Ê¼È˼°Ê×ϯִÐйÙÎâ´¿²©Ê¿µÄÁ쵼ϣ¬¶Ìʱ¼äÄÚ·¢Õ¹³ÉΪȫÊÀ½çÖªÃûµÄ¿¹ÌåºÍÉúÎïÊÔ¼ÁÑз¢£¬Éú²ú¹«Ë¾£¬ÓµÓоÑé·á¸»µÄ¼¼ÊõÑз¢¼°¹ÜÀíÍŶӣ¬¹ú¼ÊÁìÏȵIJúÆ·Éú²úÏߣ¬ÎªÊÀ½çÖî¶àÉúÎïÒ½Ò©Ñо¿»ú¹¹¡¢´óѧ¡¢Ò½Ôº¡¢ÖÆÒ©¼°Õï¶ÏÊÔ¼Á¹«Ë¾ÌṩÁËÊýÍòÖÖ×îÇ°ÑØµÄ¸ß¶Ë²úÆ·£¬¿Í»§³¬¹ý10000Óà¼Ò¡£²¢¹ººó£¬°ÙÆæÉúÎォ³ÉΪҩÃ÷¿µµÂµÄÈ«×Ê×Ó¹«Ë¾¡£Îâ´¿²©Ê¿½«µ£ÈÎÒ©Ã÷¿µµÂÉúÎïÊÔ¼Á²úÆ·¼°·þÎñ¸±×ܲ㬼ÌÐø¸ºÔð°ÙÆæÉúÎïµÄÔËÓªºÍ·¢Õ¹¡£ ÊÕ¹º°ÙÆæÉúÎïʹҩÃ÷¿µµÂÁ¢¼´ÓµÓÐÁ˹ú¼ÊÁìÏȵÄÉúÎÌåºÍÕï¶ÏÊÔ¼ÁµÄÑз¢¡¢Éú²ú¼°ÏúÊÛÄÜÁ¦£¬Ò²Ê¹µÃÒ©Ã÷¿µµÂѸËÙ½øÈë¾ßÓйãÀ«Ç°¾°µÄ¿¹ÌåºÍÕï¶ÏÊÔ¼ÁÉú²ú·þÎñÁìÓò£¬½øÒ»²½ÍêÉÆ¹«Ë¾µÄÒ»Ì廯Ñз¢·þÎñƽ̨¡£×÷ΪҽҩÑз¢·þÎñÐÐÒµµÄÁì¾üÈË£¬Ò©Ã÷¿µµÂÓµÓÐÍêÉÆµÄ·þÎñƽ̨£¬ÏíÓþÒµ½çµÄÖªÃû¶È¼°Ç¿´óµÄ¿Í»§ÍøÂç¡£°ÙÆæÉúÎï¼ÓÃËÒ©Ã÷¿µµÂ½«Ê¹ÎÒÃDZä¸ïÉúÎï¼°Õï¶ÏÊÔ¼ÁÐÐÒµ¸ñ¾Ö³ÉΪ¿ÉÄÜ£¬¸üÓÐЧµØÎªÈ«ÇòÉúÎïÒ½Ò©Ñо¿»ú¹¹¡¢´óѧ¡¢Ò½Ò©¡¢ÖÆÒ©¼°Õï¶ÏÊÔ¼Á¹«Ë¾Ìṩ¸üÍêÉÆµÄ·þÎñ£¬×îÖÕʹÎÒÃǵÄÃÎÏë¡°ÈκÎÈË¡¢Èκι«Ë¾¶¼¿ÉÒÔʹÓÃÒ©Ã÷¿µµÂµÄÑз¢Æ½Ì¨ºÍ¼¼ÊõÀ´¿ª·¢ÐÂÒ©¡±³ÉΪ¿ÉÄÜ¡£ °ÙÆæÉúÎABGENT£©¹«Ë¾ÓÚ2001ÄêÔÚÃÀ¹úÊ¥µØÑǸ磨San Diego£©³ÉÁ¢£¬ÊÇÒ»¼Ò¿ª·¢¡¢Éú²ú¡¢ÏúÊÛ¿¹Ìå¼°Õï¶ÏÊÔ¼ÁµÄÉúÎï¼¼Êõ¹«Ë¾¡£ °ÙÆæÉúÎ﹫˾ÒÑÓµÓÐÒ»Ö§¾Ñé·á¸»µÄ¶àÄÜÐͼ¼ÊõÑз¢È˲ŶÓÎéºÍÓÅÐã¡¢¿Ì¿àµÄ¹ÜÀíÍŶӣ¬ÔÚÃÀ¹úÊ¥µØÑǸçºÍÖйúÉϺ£¾ùÓµÓо«¸ÉµÄÑз¢ºÍÉú²ú²¿Ãż°¹ú¼ÊÁìÏȵÄÉèÊ©£¬ÓµÓÐÇ¿´óµÄ²úÆ·Éú²úÏߣ»²¢Òѽ¨Á¢Àι̵ÄÊг¡»ù´¡£¬ÎªÊÀ½çÖî¶àÉúÎïÒ½Ò©Ñо¿»ú¹¹¡¢´óѧ¡¢Ò½Ôº¡¢ÖÆÒ©¼°Õï¶ÏÊÔ¼Á¹«Ë¾ÌṩÁËÊýÍòÖÖÊÀ½çÉúÎï¿Æ¼¼Ñо¿×îÇ°ÑØµÄ¸ß¶Ë²úÆ·£¬ÓµÓг¬¹ý10000Óà¼Ò¿Í»§±é²¼ÊÀ½ç¸÷µØ£¬ÒÔÅ·ÃÀ¹ú¼ÒΪÖ÷¡£ °ÙÆæÉúÎ﹫˾´´°ì¿ªÊ¼¾Í×ÅÁ¦ÓÚ¿ª·¢È«ÈËÀà»ùÒò×éÏà¹Ø¿¹Ìå¡£¾¹ý¶àÄêµÄŬÁ¦£¬Ëù¿ª·¢µÄ¿¹Ìå²úÆ·ÒѸ²¸Çϸ°ûµòÍö¡¢Ï¸°û×ÔÊÉ¡¢Ï¸°û¹¦ÄÜ¡¢ÃâÒßϵͳ¡¢Éñ¾¿ÆÑ§¡¢ºËÐźš¢µ°°×ÐÞÊΡ¢¸Éϸ°ûÒÔ¼°ÌØÒìÐÔÐÞÊκó¿¹Ô¿ª·¢µÈµ°°×ÖÊ×éѧÑо¿ÁìÓò£¬Òѽ¨Á¢ÁË»ùÓÚÈËÀà»ùÒò×éµ°°×ÖÊ·ÖÀà½ÏΪÆëÈ«µÄ¿¹Ìå¿â¡£°ÙÆæÉúÎ﹫˾ͨ¹ý³ÉÊìµÄ¼¼Êõƽ̨¡¢ÓÅÐãµÄµ°°×¶àëÄÐòÁÐÉè¼Æ¼°¿¹Ìå¿âÑз¢È˲ŶÓÎéºÍ¾ßÓйú¼Ê¾ÑéµÄÉúÎïÖÆÆ·Ñо¿¹ÜÀíÍŶӣ¬³É¹¦¿ª·¢ÁËÍòÓàÖÖ´´ÐÂÐԵĿ¹Ìå²úÆ·¼°·þÎñ¡£ ͬʱ£¬°ÙÆæÉúÎï½èÖúÓÚIT¼¼ÊõºÍÉúÎïÐÅÏ¢¼¼Êõ£¬ÒÑ¿ª·¢³ö·ÖÎöÉè¼ÆSUMO»¯Î»µãºÍ¿¹Ô±íλµÄ¹¦ÄÜÇ¿´óµÄÉúÎïÈí¼þ£¬±ÈÈ磺SUMOplot, EpiShot. SUMOplotÒÑÃâ·Ñ¶ÔÍ⿪·Å£¬²»ÉÙ¿ÆÑ§¼Ò½èÖúÕâ¸öÈí¼þÈ¡µÃÁËÂúÒâµÄÑо¿³É¹û£º http://www.abgent.com/tools/sumoplot http://www.expasy.org/tools ËùÓÐÕâЩ´´ÐÂÐÔ²úÆ·¼°·þÎñʹµÃ°ÙÆæÉúÎ﹫˾ÔÚ¶Ìʱ¼äÄÚ¾ÍÒѳÉΪȫÊÀ½çÖªÃûµÄ¿¹Ìå¼°Ïà¹ØÊÔ¼Á¹«Ë¾¡£´Ó2003¡¢2004ÄêÖÁ½ñ£¬ABGENT¶à´Î±»ÊÀ½ç¶¥¼¶¿ÆÑ§ÔÓÖ¾¡±Nature¡±¡¢¡±The Scientist¡±ÁÐΪ¡±¿¹ÌåºÍµ°°×ÖÊ×鹩ӦÉÌ¡±10-50Ç¿£º Nature 2010 Antibody Company--Top26; Nature 2009 Companies offering antibodies and antibody services--Top30; Nature 2006 Companies offering Antibodies and affinity reagents--Top25; Nature 2006 Antibodies and Affinity Reagents--Top25; Nature 2004 Drug Target Identification Features--Top20; The Scientist 2004 Monitoring Phosphorylation Feature--Top10; Nature 2003 Antibody Technology--Top50; The Scientist 2003 2003Cell Signaling Feature--Top10. ÔÚ¹ú¼ÊȨÍþ¿¯ÎïÉÏ·¢±íµÄÉúÎïÒ½Ò©Ñо¿ÂÛÎÄÖУ¬Ê¹ÓÃ°ÙÆæÉúÎ﹫˾²úÆ·½øÐÐÑо¿²¢µÃµ½³É¹ûµÄÂÛÎÄÒýÓÃÆµÂÊÒÑλÓÚÈ«Çò¿¹ÌåÑз¢Éú²ú¹«Ë¾µÄǰÁС£ °ÙÆæÉúÎ﹫˾ÍŶӶàÄêÀ´ÖÂÁ¦ÓÚ½¨Á¢¸ßͨÁ¿£¨High Throughput£©¼¼ÊõÓÃÒÔ¸ßЧÂÊÉú²úµ¥¿Ë¡¿¹Ìå¡¢¶à¿Ë¡¿¹ÌåÒÔ¼°ÖØ×éµ°°×ΪºËÐĵIJúÆ·£¬Í¬Ê±¿ª·¢¾ß±¸¹ú¼Ê±ê×¼µÄϸ°ûϵ¡¢Ï¸°ûϵת»¯Éú³É¼¼ÊõºÍÊÔ¼ÁºÐ¡£°ÙÆæÉúÎ﹫˾ÕýÔÚ¼Ó¿ìÑз¢Ïà¹ØÊÔ¼ÁºÐ¡¢¿¹ÌåоƬ¡¢¶àëÄоƬµÈ£¬²¢½«ÕâЩ²úÆ·Ó¦ÓÃÓÚÖÆÒ©¹«Ë¾ËùÐèµÄÒ©Îïɸѡ¼°Ò©Ð§Óë¶¾ÐÔÆÀ¹ÀÁìÓò¡£°ÙÆæÉúÎ﹫˾ӵÓÐ¸ßÆ·Öʺ͸߸²¸ÇÂʵĿ¹Ìå¿â£¬Îª½øÒ»²½´ÓÊÂÓ¦ÓÃÓÚÕï¶Ï»òÖÎÁÆÐÔ¿¹ÌåµÄÑз¢¹¤×÷ÌṩÁË×î¼Ñƽ̨¡£ °ÙÆæÉúÎ﹫˾ĿǰµÄÖ÷Òª²úÆ·ºÍ·þÎñÀàÐÍÈçÏ£º ÉúÎïÊÔ¼Á£º ¿¹Ì壺10000¶à¸ö¶à¿Ë¡ºÍµ¥¿Ë¡¿¹Ì壬¸²¸ÇÁË×îС¢×îÈÈÃŵÄÑо¿°Ð»ùÒò¡£ ¶àëÄ£º10000¶àÌõ¿¹Ìå·â±ÕëÄ£¬3600¶àÌõ¹¦ÄÜÐÔ¶àëÄ¡£ ϸ°ûÖêºÍϸ°ûÁѽâÒº£º30¶àÖÖ³£¼ûµÄϸ°ûÖêºÍȫϸ°ûÁѽâÒº¡£ ×é֯оƬ£º100¶à¸ö×é֯оƬ£¬¼¸ºõ°üÀ¨ÈËÀàËùÓÐ×éÖ¯Æ÷¹Ù¡£ RNAi£º5800¶à¸ösiRNA²úÆ·£¬HPLC´¿»¯£¬ÒÖÖÆÐ§Âʿɴï70%ÒÔÉÏ¡£ ¶¨ÖÆ·þÎñ£º ¿¹ÌåÖÆ±¸£º ÍÃÔ´¶à¿Ë¡¿¹Ìå ÊóÔ´µ¥¿Ë¡¿¹Ìå ÍÃÔ´ÖØ×éµ¥¿Ë¡¿¹Ìå ¿¹Ô±íÎ»ÌØÒìÐÔ ¶àëÄ¿¹Ô¡¢µ°°×¿¹Ô ÌØÒìÐÔÐÞÊο¹Ìå ¶àëĺϳɣº ¸ß´¿¶È³¤ëÄ£¨50-100¸ö°±»ùËᣩ ¸´ÔÓÐòÁÐ ¶àëÄÐÞÊÎ ¶àëÄÎĿ⠵°°×±í´ï£º ϸ¾ú±í´ïϵͳ ¸Ë×´²¡¶¾±í´ïϵͳ ²¸È鶯Îïϸ°û±í´ïϵͳ °ÙÆæÉúÎ﹫˾µÄ¼¼Êõר¼ÒõÒÉí¹ú¼ÊѧÊõÇ°ÑØ£¬Í¬Ê±ÓëPfizer¡¢Aventis¡¢Wyeth¡¢NIH¡¢Merck¡¢BD Biosciences¡¢Invitrogen¡¢Millipore¡¢Sigma¡¢BioRad¡¢EMD Biosciences¡¢Abcam¡¢Origene¡¢Cell Signaling Technologies¡¢AbnovaµÈ¹ú¼ÊÖªÃû¹«Ë¾£¬¹þ·ð´óѧ¡¢Ë¹Ì¹¸£´óѧ¡¢Öйú¿ÆÑ§ÔºÏ¸°ûÉú»¯Ñо¿Ëù¡¢Ò©ÎïÑо¿Ëù¡¢Î¢ÉúÎïÑо¿Ëù¡¢Ö²ÎïÑо¿Ëù¡¢±±¾©´óѧ¡¢¸´µ©´óѧ¡¢ÉϺ£½»Í¨´óѧ¡¢ÖÐɽ´óѧ¡¢ÄÏ¿ª´óѧ¡¢ÖÐÄÏ´óѧµÈ¿ÆÑÐÔºËù½¨Á¢Á˳¤ÆÚµÄÏîÄ¿ºÏ×÷¹ØÏµ£¬´Ó¶ø±£Ö¤¹«Ë¾¼¼ÊõµÄÏȽøÐԺͿɳÖÐø·¢Õ¹¡£ °ÙÆæÉúÎï¿Æ¼¼£¨ËÕÖÝ£©ÓÐÏÞ¹«Ë¾Ò²ÊÇABGENTµÄÈ«×Ê×Ó¹«Ë¾£¬Æä²úÆ·Ñз¢Éú²úƽ̨ÒÑͨ¹ýISO9001-2008ÖÊÁ¿¹ÜÀíÌåϵSGSÈÏÖ¤¡£ [ Last edited by Ò©Ãû¿µµÂ on 2011-10-14 at 09:41 ] |
» ²ÂÄãϲ»¶
Çóµ÷¼Á
ÒѾÓÐ23È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
304Çóµ÷¼Á£¨085602£¬¹ýËļ¶£¬Ò»Ö¾Ô¸985£©
ÒѾÓÐ17È˻ظ´
302·ÖÇóµ÷¼Á Ò»Ö¾Ô¸°²»Õ´óѧ085601
ÒѾÓÐ12È˻ظ´
288»·¾³×¨Ë¶,Çóµ÷²ÄÁÏ·½Ïò
ÒѾÓÐ23È˻ظ´
»·¾³×¨Ë¶µ÷¼Á
ÒѾÓÐ6È˻ظ´
22408 µ÷¼Á²ÄÁÏ
ÒѾÓÐ6È˻ظ´
285Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ19È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ѯÎÊÎ人ҩÃ÷¿µµÂÈËÁ¦×ÊÔ´²¿µç»°
ÒѾÓÐ3È˻ظ´
Ò©Ã÷¿µµÂµç»°ÃæÊÔ
ÒѾÓÐ11È˻ظ´
ÖøÃûCROÒ©Ã÷¿µµÂÕÐÆ¸(ÄÜÂíÉϵ½¸Ú£¬ÓÐÏà¹ØºÏ³É¾ÑéµÄÇëºÍÎÒÁªÏµ)
ÒѾÓÐ54È˻ظ´
ÑÇÖÞµÚÒ»ÐÂÒ©¡°Íâ°üÉÌ¡±Ò©Ã÷¿µµÂÈëפÎ人¹â¹ÈÉúÎï³Ç
ÒѾÓÐ10È˻ظ´
ÉϺ£Ò©Ã÷¿µµÂÐÂÒ©Ñз¢ÓÐÏÞ¹«Ë¾ÕÐÆ¸À²
ÒѾÓÐ9È˻ظ´
ÓÐÔÚÒ©Ã÷¿µµÂÎÞÎýÉú²ú»ùµØ£¨ÎÞÎýÒ©Ã÷¿µµÂÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾ £©»ò¶ÔËüÓÐËùÁ˽âµÄÂð
ÒѾÓÐ30È˻ظ´
Ò©Ã÷¿µµÂÊÇÈ¥Î人»¹ÊÇÈ¥ÉϺ£
ÒѾÓÐ34È˻ظ´
WuXi PharmaTech Acquires Abgent, a Leading Producer of Biological Research
ÒѾÓÐ6È˻ظ´
Ò©Ã÷¿µµÂ
ÒѾÓÐ16È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿Ò©Ã÷¿µµÂºÃÂð£¿
ÒѾÓÐ13È˻ظ´

wuyan5962
ÈÙÓþ°æÖ÷ (Ö°Òµ×÷¼Ò)
µÂÏÈÉúºÍÈüÏÈÉú
- Ó¦Öú: 8 (Ó×¶ùÔ°)
- ¹ó±ö: 4.391
- ½ð±Ò: 9894
- É¢½ð: 9982
- ºì»¨: 64
- ɳ·¢: 9
- Ìû×Ó: 3213
- ÔÚÏß: 804.7Сʱ
- ³æºÅ: 1036692
- ×¢²á: 2010-06-06
- ÐÔ±ð: GG
- רҵ: Ò©¼Áѧ
- ¹ÜϽ: ±ê×¼ÓëרÀû½»Á÷

2Â¥2011-10-14 12:29:25
Ò©µÀÈË
ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
¾»ÓÉ»àÉú£¬Ã÷´Ó霳ö
-

ר¼Ò¾Ñé: +71 - PhEPI: 1
- Ó¦Öú: 38 (СѧÉú)
- ¹ó±ö: 6.92
- ½ð±Ò: 27026.1
- É¢½ð: 9994
- ºì»¨: 143
- ɳ·¢: 178
- Ìû×Ó: 25008
- ÔÚÏß: 1356.1Сʱ
- ³æºÅ: 336426
- ×¢²á: 2007-04-01
- ÐÔ±ð: GG
- רҵ: µÀ½Ì
- ¹ÜϽ: ½ðÈÚͶ×Ê
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÊÕ¹ºÒ»¼ÒÊÔ¼Á¹«Ë¾Ò²ºÃÒâ˼ÄóöÀ´£¬²»ÒªÒÔΪÉϹýÐÂÎÅÁª²¥¾ÍÁ˲»ÆðabgentÊÀ½çÖªÃû£¿cst£¬abmart£¬abnova£¬abcam£¬santaµÈµÈ±íʾÑÇÀúɽ´ó |

3Â¥2011-10-14 13:40:26














»Ø¸´´ËÂ¥

ÊÕ¹ºÒ»¼ÒÊÔ¼Á¹«Ë¾Ò²ºÃÒâ˼ÄóöÀ´£¬²»ÒªÒÔΪÉϹýÐÂÎÅÁª²¥¾ÍÁ˲»Æð